Komori
Mochida Pharmaceutical (4534) · RiskRestated

Risk of Conflicts with Third-Party Intellectual Property Rights

First written in FY2016. 7 of 8 entries say "Restated". Latest entry: FY2026.

8entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20262016: 120162017: 020172018: 120182019: 120192020: 120202021: 120212022: 120222023: 020232024: 020242025: 120252026: 12026
Same theme, other companies
Risk of Infringing Third-Party Intellectual Property RightsA theme 465 companies write about · 468 as a headwind · 1 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 469 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026RestatedAnnual report

    「If the Group's business activities infringe third-party intellectual property rights, lower earnings resulting from litigation, damages and royalty payments could ultimately lead to business suspension and have a material impact on operating results and financial condition.」

    The risks of litigation, damages, royalty payments and business suspension arising from infringement of third-party intellectual property rights have been reconfirmed.
  2. FY2025RestatedAnnual report

    「If the Group's business activities infringe third-party intellectual property rights, lower earnings resulting from litigation, damages and royalty payments could ultimately lead to business suspension and have a material impact on operating results and financial condition.」

    The risks of litigation, damages, royalty payments and business suspension arising from infringement of third-party intellectual property rights have been reconfirmed.
  3. FY2022RestatedAnnual report

    「If the Group's business activities infringe third-party intellectual property rights, lower earnings resulting from litigation, damages and royalty payments could ultimately lead to business suspension and have a material impact on operating results and financial condition.」

    The risks of litigation, damages, royalty payments and business suspension arising from infringement of third-party intellectual property rights have been reconfirmed.
  4. FY2021RestatedAnnual report

    「If the Group's business activities infringe third-party intellectual property rights, lower earnings resulting from litigation, damages and royalty payments could ultimately lead to business suspension and have a material impact on operating results and financial condition.」

    The risks of litigation, damages, royalty payments and business suspension arising from infringement of third-party intellectual property rights have been reconfirmed.
  5. FY2020RestatedAnnual report

    「If the Group's business activities infringe third-party intellectual property rights, lower earnings resulting from litigation, damages and royalty payments could ultimately lead to business suspension and have a material impact on operating results and financial condition.」

    The risks of litigation, damages and business suspension arising from infringement of third-party intellectual property rights are reiterated.
  6. FY2019RestatedAnnual report

    「If the Group's business activities infringe third-party intellectual property rights, this could lead to litigation or suspension of the business.」

    The risks of litigation and business suspension arising from infringement of third-party intellectual property rights are reiterated.
  7. FY2018RestatedAnnual report

    「If the Group's business activities infringe third-party intellectual property rights, this could lead to litigation or suspension of the business.」

    The risk of infringement of third-party intellectual property rights is reiterated.
  8. FY2016First statedAnnual report

    「If the Group's business activities infringe third-party intellectual property rights, this could lead to litigation or suspension of the business.」

    The disclosure also states that the Group strives to manage its intellectual property rights and avoid infringing third-party rights.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Mochida Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.